DE69433666D1 - ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma - Google Patents

ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma

Info

Publication number
DE69433666D1
DE69433666D1 DE69433666T DE69433666T DE69433666D1 DE 69433666 D1 DE69433666 D1 DE 69433666D1 DE 69433666 T DE69433666 T DE 69433666T DE 69433666 T DE69433666 T DE 69433666T DE 69433666 D1 DE69433666 D1 DE 69433666D1
Authority
DE
Germany
Prior art keywords
polypeptides
mip
inflammatory protein
macrophage inflammatory
human macrophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433666T
Other languages
English (en)
Other versions
DE69433666T2 (de
Inventor
Haodong Li
A Rosen
Steven M Ruben
D Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/173,209 external-priority patent/US5556767A/en
Priority claimed from US08/208,339 external-priority patent/US5504003A/en
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of DE69433666D1 publication Critical patent/DE69433666D1/de
Application granted granted Critical
Publication of DE69433666T2 publication Critical patent/DE69433666T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
DE69433666T 1993-12-22 1994-06-28 ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma Expired - Lifetime DE69433666T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US208339 1988-06-16
US08/173,209 US5556767A (en) 1993-12-22 1993-12-22 Polynucleotide encoding macrophage inflammatory protein γ
US173209 1993-12-22
US08/208,339 US5504003A (en) 1994-03-08 1994-03-08 Macrophage inflammatory protein-3 and -4
PCT/US1994/007256 WO1995017092A1 (en) 1993-12-22 1994-06-28 MACROPHAGE INFLAMMATORY PROTEINS-3, -4 AND -1¿η?

Publications (2)

Publication Number Publication Date
DE69433666D1 true DE69433666D1 (de) 2004-05-06
DE69433666T2 DE69433666T2 (de) 2005-03-03

Family

ID=26868880

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433666T Expired - Lifetime DE69433666T2 (de) 1993-12-22 1994-06-28 ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma

Country Status (12)

Country Link
EP (1) EP0735818B1 (de)
JP (2) JP3677288B2 (de)
KR (1) KR970700438A (de)
CN (2) CN1143894A (de)
AT (1) ATE262914T1 (de)
CA (1) CA2179606A1 (de)
DE (1) DE69433666T2 (de)
DK (1) DK0735818T3 (de)
ES (1) ES2214484T3 (de)
NZ (1) NZ271756A (de)
PT (1) PT735818E (de)
WO (1) WO1995017092A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
US6180773B1 (en) * 1994-04-30 2001-01-30 Wolf-Georg Forssmann Tandem cDNAs encoding chemokines CC-1, CC-2, and CC-3
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
US5770402A (en) * 1995-04-05 1998-06-23 Board Of Regents, The University Of Texas System DNA encoding macrophage inflammatory protein-1γ
US5874211A (en) * 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils
MX9708537A (es) * 1995-05-05 1998-02-28 Human Genome Sciences Inc Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas.
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6790947B1 (en) 1995-06-07 2004-09-14 Icos Corporation Polynucleotides encoding macrophage derived chemokine
US5688927A (en) * 1995-06-07 1997-11-18 Icos Corporation Macrophage derived chemokine
US6320023B1 (en) 1995-06-07 2001-11-20 Icos Corporation Macrophage derived chemokine
HUP9701282A3 (en) * 1995-06-07 1999-09-28 Icos Corp Bothell Macrophage derived chemokine and chemokine analogs
EA199800352A1 (ru) * 1995-09-29 1998-12-24 Смитклайн Бичам Корпорейшн ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
US6713052B1 (en) 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1422239A3 (de) * 1995-10-24 2004-12-01 Smithkline Beecham Corporation Aktivierung von haematopoietischen Stammzellen durch Anwendung einer Chemokine
WO1997015594A1 (en) * 1995-10-24 1997-05-01 Smithkline Beecham Corporation Novel chemokine for mobilizing stem cells
ZA97990B (en) * 1996-02-09 1997-08-06 Schering Corp Mammalian dendritic cell chemokine reagents.
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
WO1997042224A1 (en) * 1996-05-07 1997-11-13 Millennium Biotherapeutics, Inc. Neurotactin and uses therefor
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US5981231A (en) 1996-06-17 1999-11-09 Human Genome Sciences, Inc. Polynucleotides encoding chemokine β-15
AU4233797A (en) * 1996-08-23 1998-03-06 Human Genome Sciences, Inc. Chemokine beta-16
JP2001500382A (ja) * 1996-09-30 2001-01-16 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド 骨髄前駆体阻害因子―1(mpif―1)、単球コロニー阻害因子(m―cif)、およびマクロファージ阻害因子―4(mip―4)で疾患状態を処置するための治療組成物および方法
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
WO1998017800A1 (fr) * 1996-10-17 1998-04-30 Shionogi & Co., Ltd. Larc, nouvelle chimiokine cc humaine
EP0848012A1 (de) 1996-12-13 1998-06-17 Roche Diagnostics GmbH Verwendung von Polypeptiden zur Behandlung von Thrombozytopenien
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
EP1093516A2 (de) * 1998-07-06 2001-04-25 Schering Corporation Säugergenen; dendritische zellen prostaglandin- förmigen transporterprotein (dc-pgt), hdtea84, hsljd37r und rankl, hcc5 chemokine, deubiquitine 11 und 12 (dub11, dub12), md-1, md2 und cyclin e2, zugehörige reagenzien und verfahren
EP0974357A1 (de) * 1998-07-16 2000-01-26 Schering-Plough Chemokine als Adjuvantien der Immunantwort
WO2000028035A1 (en) 1998-11-10 2000-05-18 Human Genome Sciences Inc. CHEMOKINE β-7
JP4605884B2 (ja) * 2000-10-19 2011-01-05 独立行政法人科学技術振興機構 インフルエンザウイルスウイルスrnaポリメラーゼの製法
US20030077247A1 (en) * 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
CA2484121A1 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
WO2005057220A2 (en) 2003-12-05 2005-06-23 Oxagen Limited Agents modulating the activity of ccrl2 and methods of using the same
WO2012068540A2 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
US10527544B2 (en) * 2015-06-12 2020-01-07 Georgia State University Research Foundation, Inc. ATR-FTIR for non-invasive detection of colitis
US11280732B2 (en) 2018-08-20 2022-03-22 Georgia State University Research Foundation, Inc. Detection of melanoma and lymphoma by ATR-FTIR spectroscopy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091266A1 (en) * 1990-09-14 1992-03-15 Patricia Tekamp-Olson Expression of macrophage inducible proteins (mips) in yeast cells

Also Published As

Publication number Publication date
EP0735818B1 (de) 2004-03-31
EP0735818A1 (de) 1996-10-09
JP2002053490A (ja) 2002-02-19
CN1321745A (zh) 2001-11-14
DE69433666T2 (de) 2005-03-03
NZ271756A (en) 1998-02-26
JP3677288B2 (ja) 2005-07-27
WO1995017092A1 (en) 1995-06-29
CN1143894A (zh) 1997-02-26
CA2179606A1 (en) 1995-06-29
DK0735818T3 (da) 2004-07-26
KR970700438A (ko) 1997-02-12
ATE262914T1 (de) 2004-04-15
EP0735818A4 (de) 1997-07-02
ES2214484T3 (es) 2004-09-16
AU684539B2 (en) 1997-12-18
AU7549794A (en) 1995-07-10
JPH09506774A (ja) 1997-07-08
PT735818E (pt) 2004-07-30

Similar Documents

Publication Publication Date Title
DE69433666D1 (de) ENTZÜNDUNGSPROTEINE AUS MAKROPHAGEN MIP-3, MIP-4 UND MIP-1Gamma
ATE179429T1 (de) Cytokine dämpfende substanzen
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ID28299A (id) Protein-protein reseptor seperti toll manusia metoda-metoda dan reagen-reagen yang berhubungan
PT737207E (pt) Inibidores de plasmina humana derivados de dominios kunitz
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69822307D1 (de) Menschliches adamts-1 protein, gen , welches für dieses kodiert, pharmazeutische zusammensetzung und verfahrem zur immunologischen bestimmung von menschlichen adamts-1 proteinen
DE59209196D1 (de) Menschliche il-4 mutantenproteine
ATE249835T1 (de) Immunoregulator
DE69428460D1 (de) Chemotaktisches protein
IL145689A0 (en) Methods
BR0312889A (pt) Polipeptìdeo t20 peguilado
ATE303439T1 (de) Intrazelluläre isoform von interleukin-1 rezeptor antagonist
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
BR0114977A (pt) segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE69529235T2 (de) Menschliche dnase i varianten
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
ATE231887T1 (de) Protein mit anti-tumorwirkung
ITRM920516A1 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.
ITRM940453A0 (it) "uso della proteina p1lsa per la preparazione di un medicamento da utilizzarsi nella terapia di patologie indotte da danni cellulari da agenti fisici, chimici o biologici"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition